Shopping Cart
- Remove All
Your shopping cart is currently empty
NUCC-390
Catalog No. T12269Cas No. 1060524-97-1
NUCC-390, a novel small-molecule CXCR4 receptor agonist, selectively induces CXCR4 receptor internalization while acting antagonistically to AMD3100. This compound facilitates nerve functional recovery following neurodegeneration in vivo.
NUCC-390
Catalog No. T12269Cas No. 1060524-97-1
NUCC-390, a novel small-molecule CXCR4 receptor agonist, selectively induces CXCR4 receptor internalization while acting antagonistically to AMD3100. This compound facilitates nerve functional recovery following neurodegeneration in vivo.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $151 | In Stock | |
| 5 mg | $318 | In Stock | |
| 10 mg | $498 | In Stock | |
| 25 mg | $812 | In Stock | |
| 50 mg | $1,130 | In Stock | |
| 100 mg | $1,520 | In Stock | |
| 500 mg | $2,970 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $377 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "NUCC-390"
Nicotinamide N-oxide
Nicotinamide-N-oxide, Nicotinamide 1-oxide, 1-oxynicotinamide
T06171986-81-8
Nicotinamide N-oxide (Nicotinamide 1-oxide) is recognized as an in vivo metabolite of nicotinamide which is a precurser of nicotinamide-adenine dinucleotide (NAD+) in animals. The enzyme that catalyzes the reduction of nicotinamide N-oxide to nicotinamide in the liver is xanthine oxidase.
- $33
Size
QTY
Artemotil
Cited
β-Arteether, SM-227, Beta-Arteether, Arteether, (+)-Arteether
T332775887-54-6
Artemotil (SM-227) is a new, fast-acting antimalarial drug.
- $50
Size
QTY
CitedPlerixafor Cited
JM3100, AMD-3329, AMD 3100
T1776110078-46-1
Plerixafor (AMD-3329), a chemokine receptor antagonist, blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4.
- $42
Size
QTY
CitedPlerixafor octahydrochloride Cited
SID791 octahydrochloride, Plerixafor 8HCl (AMD3100 8HCl), Plerixafor 8HCl, JM3100 octahydrochloride, JM 3100 8HCl, AMD 3100 octahydrochloride
T1776L155148-31-5
Plerixafor octahydrochloride (JM3100 octahydrochloride) blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation. Plerixafor is a bicyclam with hematopoietic stem cell-mobilizing activity.
- $42
Size
QTY
CitedCXCR2-IN-1
T109051873376-49-8In house
CXCR2-IN-1 has a pIC50 of 9.3 and is a CXCR2 antagonist of the central nervous system penetration agent.
- $73
Size
QTY
AZD8309
AZD-8309, AZD 8309
T25131333742-48-6In house
AZD8309 is a potent, orally available antagonist of the chemokine receptor CXCR2 that regulates neutrophil transport, significantly reduces MPO in the pancreas and lung, and decreases trypsin and elastase activity in the pancreas.AZD8309 can be used to study a range of inflammatory diseases.
- $129
Size
QTY
rac-NBI-74330
racNBI74330, rac NBI 74330
T26035473722-68-8In house
rac-NBI-74330 is an effective and selective CXCR3 antagonist.
- $88
Size
QTY
LIT927
LIT-927, LIT 927
T52072172879-52-4
LIT927 (LIT-927) is an orally active CXCL12 neutraligand (Ki: 267 nM for CXCL12 binding to CXCR4).
- $35
Size
QTY
Delmetacin
Demethacin
T6805216401-80-2In house
Delmetacin (Demethacin) is a non-steroidal anti-inflammatory compound with anti-inflammatory and analgesic activity and inhibitory effects on the CXC chemokine receptor CXCR1.
- $75
Size
QTY
CXCL-CXCR1/2-IN-1
T843252415653-55-1
CXCL-CXCR1/2-IN-1 is an orally active and potent inhibitor of the ELR+CXCL-CXCR1/2 pathway with anticancer and anti-angiogenic activity and can be used to study cardiovascular disease and cancer.
- $40
Size
QTY
Reparixin Cited
Repertaxin, DF 1681Y
T4163266359-83-5
Reparixin (Repertaxin) is a potent inhibitor of both CXCL8 receptors CXCR1/2, it inhibits weakly CXCR2-mediated cell migration (IC50=100 nM), whereas it strongly blocks CXCR1-mediated chemotaxis (IC50=1 nM).
- $48
Size
QTY
CitedSelect Batch
Purity:98.18%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | NUCC-390, a novel small-molecule CXCR4 receptor agonist, selectively induces CXCR4 receptor internalization while acting antagonistically to AMD3100. This compound facilitates nerve functional recovery following neurodegeneration in vivo. |
| In vitro | NUCC-390 (10 μM) elicits a strong (Ca)i response, which can be blocked by the potent and selective CXCR4 antagonist AMD3100. Pre-treatment with NUCC-390 (10 μM; 30 mins) increases pERK levels, stimulating signaling activity downstream of CXCR4 receptors. NUCC-390 (10 μM; 2 hours) induces CXCR4 receptor internalization, while non-treated cells show diffuse CXCR4-YFP expression in the cytosol and clear membrane expression in HEK cells[1]. Additionally, NUCC-390 (0-1.25 μM; 24 hours) enhances axonal growth in cultured cerebellar granule neurons (CGNs) via CXCR4[2]. |
| In vivo | NUCC-390 (hind limb injection; 3.2 mg/kg; twice daily; 3 days) enhances functional and anatomical recovery of the neuromuscular junction (NMJ) after acute nerve terminal damage by α-LTx in CD-1 mice[2]. |
| Molecular Weight | 395.54 |
| Formula | C23H33N5O |
| Cas No. | 1060524-97-1 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/mL (151.69 mM)  | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy NUCC-390 | purchase NUCC-390 | NUCC-390 cost | order NUCC-390 | NUCC-390 chemical structure | NUCC-390 in vivo | NUCC-390 in vitro | NUCC-390 formula | NUCC-390 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.